Top

Published in:

01-08-2020 | Colchicine | Letter to the Editor

Colchicine as a possible therapeutic option in COVID-19 infection

Authors: Rafael Parra-Medina, Juan Camilo Sarmiento-Monroy, Adriana Rojas-Villarraga, Edgar Garavito, Giovanni Montealegre-Gómez, Arley Gómez-López

Published in: Clinical Rheumatology | Issue 8/2020

Excerpt

Dear Editor, …

Cumhur Cure M, Kucuk A, Cure E (2020) Colchicine may not be effective in COVID-19 infection; it may even be harmful? Clin Rheumatol:12–13

Nuki G (2008) Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep 10(3):218–227CrossRef

Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y et al (2020) Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis

Martínez GJ, Celermajer DS, Patel S (2018) The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 269:262–271CrossRef

Conti P, Ronconi G, Caraffa A, Gallenga C, Ross R, Frydas I et al (2020) Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents 34(2)

Maurizi M, Delorme N, Laprévote-Heully MC, Lambert H, Larcan A (1986) Syndrome de détresse respiratoire aiguë de l’adulte au cours des intoxications par la colchicine. Ann Fr Anesth Reanim 5(5):530–532CrossRef

Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, Pollak U, Koren G, Bentur Y (2010) Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol 48(5):407–414CrossRef

Montealegre-Gómez G, Garavito E, Gómez-López A, Rojas-Villarraga A, Parra-Medina R (2020) Colchicine: a potential therapeutic tool against COVID-19. Experience of 5 patients. Reumatol Clín

Dabbagh MF, Aurora L, D’Souza P, Weinmann AJ, Bhargava P, Basir MB (2020) Cardiac Tamponade secondary to COVID-19. JACC Case Rep

10.

Altschuler EL (2004) Colchicine for respiratory syncytial virus bronchiolitis. Lancet. 363(9424):1911CrossRef

11.

Lu N, Yang Y, Liu H, Ding X, Ou Y, Xia J et al (2019) Inhibition of respiratory syncytial virus replication and suppression of RSV-induced airway inflammation in neonatal rats by colchicine. 3 Biotech 9(11):392CrossRef

12.

Boulis NM, Willmarth NE, Song DK, Feldman EL, Imperiale MJ (2003) Intraneural colchicine inhibition of adenoviral and adeno-associated viral vector remote spinal cord gene delivery. Neurosurgery. 52(2):381–387CrossRef

13.

Bosem M, Harris R, Atherton SS. Optic nerve involvement in viral spread in herpes simplex virus type 1 retinitis. Invest Ophthalmol Vis Sci 1990;31(9):1683–1689

14.

Nouchi A, Monsel G, Lafon-Desmurs B, Meng L, Burrel S, Moyal-Barracco M, Caumes E (2018) Epstein-Barr virus-related acute genital ulcer successfully treated with colchicine. Acta Derm Venereol 98(1):134–135CrossRef

15.

Arrieta O, Rodriguez-Diaz JL, Rosas-Camargo V, Morales-Espinosa D, de Leon SP, Kershenobich D, Leon-Rodriguez E (2006) Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus-related liver cirrhosis. Cancer. 107(8):1852–1858CrossRef

16.

Floreani, Lobello, Brunetto, Aneloni, Chiaramonte (1998) Colchicine in chronic hepatitis B: a pilot study. Aliment Pharmacol Ther 12(7):653–656CrossRef

Title: Colchicine as a possible therapeutic option in COVID-19 infection
Authors: Rafael Parra-Medina
Juan Camilo Sarmiento-Monroy
Adriana Rojas-Villarraga
Edgar Garavito
Giovanni Montealegre-Gómez
Arley Gómez-López
Publication date: 01-08-2020
Publisher: Springer International Publishing
Keywords: Colchicine
Gout
Acute Respiratory Distress-Syndrome
COVID-19
Published in: Clinical Rheumatology / Issue 8/2020
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-05247-5

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Colchicine as a possible therapeutic option in COVID-19 infection

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2020

Correction to: Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis

Serum amino acid metabolic profiles of ankylosing spondylitis by targeted metabolomics analysis

Comment on “Quantitative measures of tissue mechanics to detect hypermobile Ehlers-Danlos syndrome and hypermobility syndrome disorders: a systematic review”

Tocilizumab treatment effectively improves coronary artery involvement in patients with Takayasu arteritis

Differentially expressed lncRNAs in peripheral blood mononuclear cells from middle-aged female patients with rheumatoid arthritis–associated interstitial lung disease

Response to “Quantitative measures of tissue mechanics to detect hypermobile Ehlers Danlos syndrome and hypermobility syndrome disorders: a systematic review”

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page